Centre de Lutte Contre le Cancer - Institut de Cancerologie de l'Ouest - Rene Gauducheau

SaintHerblain 44805

0 studies enrolling now · 9 studies all time

What they study most

Bladder Cancer, Endometrial Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Head and Neck Cancer, Locally Advanced Solid Tumors, Metastatic Cholangiocarcinoma, Metastatic Solid Tumors, Metastatic Urothelial Carcinoma, Muscle Invasive Bladder Cancer, NSCLC, Non-small Cell Lung Cancer, Renal Pelvis Carcinoma

Studies at this site

• Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. — Completed
• A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer — Stopped early
• Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck — Running, not enrolling
• Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). — Completed
• A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma — Stopped early
• A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202) — Completed
• A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors — Completed
• A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma — Completed
• Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma — Stopped early